ICU Medical reported Q3 revenue of $556 million, up 5% organically, with adjusted EBITDA of $114 million and adjusted EPS of $2.44; full-year guidance points toward the higher end of $415 to $435 million EBITDA and $8.60 to $9 EPS.
ICUI · Icu Medical Inc · Documents
One customer — 20% of revenue (three months ended September 30, 2026)
“For the three and nine months ended September 30, 2026, our consolidated worldwide net sales to a single distributor were 20%, and 19%, respectively, and for the three and nine months ended September 30, 2025, were 17% and 17%.”
One customer — 19% of revenue (nine months ended September 30, 2026)
“For the three and nine months ended September 30, 2026, our consolidated worldwide net sales to a single distributor were 20%, and 19%, respectively, and for the three and nine months ended September 30, 2025, were 17% and 17%.”
One customer — 17% of revenue (nine months ended September 30, 2025)
“For the three and nine months ended September 30, 2026, our consolidated worldwide net sales to a single distributor were 20%, and 19%, respectively, and for the three and nine months ended September 30, 2025, were 17% and 17%.”
One customer — 17% of revenue (three months ended September 30, 2025)
“For the three and nine months ended September 30, 2026, our consolidated worldwide net sales to a single distributor were 20%, and 19%, respectively, and for the three and nine months ended September 30, 2025, were 17% and 17%.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
ICU Medical, Inc. reported a 41.2% gross margin for the nine months ended September 30, 2026, up from 36.6%, with $29.2 million in tariff refunds boosting cost of goods sold.
ICU Medical reported third-quarter GAAP revenue of $560.4 million and net income of $26.8 million, or $1.07 per diluted share. It reaffirmed fiscal year 2026 guidance and expects results near the high end.